EPRX · Eupraxia Pharmaceuticals Inc.
Market Cap
$441.04M
Shares
66.07M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| 6-K | 2026-08-13 | — | |
| 6-K | 2026-08-11 | — | |
| 6-K | 2026-07-15 | — | |
| 6-K | 2026-07-13 | — | |
| 6-K | 2026-07-07 | — | |
| Investor Event Transcript | 2026-06-30 | — | |
| 6-K | 2026-06-22 | 2026-06-19 | |
| 6-K | 2026-05-29 | 2026-06-18 | |
| 6-K | 2026-05-29 | 2026-05-28 | |
| 6-K | 2026-05-28 | — | |
| 6-K | 2026-05-12 | — | |
| 6-K | 2026-05-06 | — | |
| 6-K | 2026-05-05 | — | |
| 6-K | 2026-05-01 | — | |
| 6-K | 2026-04-22 | — | |
| 6-K | 2026-04-21 | — | |
| Investor Event Transcript | 2026-04-21 | 2026-06-30 | |
| 6-K | 2026-04-15 | 2026-04-14 | |
| 6-K | 2026-04-15 | 2026-04-14 | |
| 6-K | 2026-03-17 | — | |
| 40-F | 2026-03-13 | 2025-12-31 | |
| 6-K | 2026-03-06 | 2026-02-23 | |
| 6-K | 2026-02-20 | 2026-02-19 | |
| 6-K | 2026-02-20 | — | |
| 6-K | 2026-02-19 | — | |
| 6-K | 2026-02-18 | — | |
| 6-K | 2026-01-08 | — | |
| 6-K | 2025-11-13 | — | |
| 6-K | 2025-11-04 | — | |
| 6-K | 2025-10-01 | 2025-09-29 | |
| 6-K | 2025-09-29 | — | |
| 6-K | 2025-09-24 | — | |
| 6-K | 2025-09-23 | — | |
| 6-K | 2025-09-23 | 2025-09-22 | |
| 6-K | 2025-09-22 | — | |
| 6-K | 2025-09-19 | — | |
| 6-K | 2025-09-02 | — | |
| 6-K | 2025-08-13 | 2025-08-12 | |
| 6-K | 2025-07-22 | — | |
| 6-K | 2025-07-08 | — | |
| 6-K | 2025-06-03 | 2025-06-02 | |
| 6-K | 2025-06-02 | 2025-05-30 | |
| 6-K | 2025-05-07 | — | |
| 6-K | 2025-05-06 | — | |
| 6-K | 2025-05-05 | — | |
| 6-K | 2025-04-24 | — | |
| 6-K | 2025-03-21 | 2025-03-20 | |
| 40-F | 2025-03-20 | 2024-12-31 | |
| 6-K | 2025-02-25 | — | |
| 6-K | 2025-02-18 | — |
Showing 1–50 of 88 filings
Key facts
CIK
1581178
CUSIP
29842P105
13F (30d)
68 filings
66 filers
Visit website
Investor relations